Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
Theriva Biologics (NYSE American: TOVX) entered a warrant inducement agreement to accelerate the exercise of existing warrants for up to 7,360,460 shares at a reduced price of $0.54 per share, generating approximately $4.0 million in gross proceeds, with an offer window to raise up to an additional $0.4 million. In return, investors will receive new unregistered warrants to purchase up to 14,720,920 shares at $0.54, exercisable after stockholder approval and expiring five years after the Approval Date. Closing is expected on or about October 17, 2025. Net proceeds are intended for working capital and general corporate purposes. A.G.P./Alliance Global Partners acted as exclusive financial advisor.
Theriva Biologics (NYSE American: TOVX) ha stipulato un accordo di induzione dei warrant per accelerare l’esercizio dei warrant esistenti per un massimo di 7.360.460 azioni a un prezzo ridotto di $0,54 per azione, generando proventi lordi di circa $4,0 milioni, con una finestra di offerta per raccogliere fino a ulteriori $0,4 milioni. In cambio, gli investitori riceveranno nuovi warrant non registrati per l’acquisto di fino a 14.720.920 azioni a $0,54, esercitabili dopo l’approvazione degli azionisti e scadenti cinque anni dopo la data di approvazione. La chiusura è prevista indicativamente per il 17 ottobre 2025. Il ricavato netto è destinato al capitale circolante e agli usi societari generali. A.G.P./Alliance Global Partners ha agito come consulente finanziario esclusivo.
Theriva Biologics (NYSE American: TOVX) firmó un acuerdo de inducción de warrants para acelerar el ejercicio de warrants existentes por hasta 7,360,460 acciones a un precio reducido de $0,54 por acción, generando ingresos brutos de aproximadamente $4,0 millones, con una ventana de oferta para recaudar hasta otros $0,4 millones. A cambio, los inversionistas recibirán nuevos warrants no registrados para comprar hasta 14,720,920 acciones a $0,54, exercitables tras la aprobación de los accionistas y que vencen cinco años después de la Fecha de Aprobación. El cierre se espera alrededor del 17 de octubre de 2025. Los ingresos netos se destinarán a capital de trabajo y fines corporativos generales. A.G.P./Alliance Global Partners actuó como asesor financiero exclusivo.
Theriva Biologics (NYSE American: TOVX)는 기존 워런트를 행사 속도를 높이기 위한 권유 계약을 체결하여 주당 $0.54의 할인된 가격으로 최대 7,360,460주의 워런트를 행사하도록 촉진하고, 약 $4.0백만의 총 수익을 창출하며 추가로 $0.4백만을 모금할 수 있는 공모 창을 제공합니다. 그 대가로 투자자들은 주주 승인 후 행사 가능하고 승인일로부터 5년 동안 만료되는 $0.54에 매수할 수 있는 새롭고 비등록된 워런트를 받게 됩니다. 마감은 2025년 10월 17일경으로 예상됩니다. 순매출은 운전자본 및 일반 기업 목적에 사용될 예정입니다. A.G.P./Alliance Global Partners가 독점 재무 자문 역할을 했습니다.
Theriva Biologics (NYSE American: TOVX) a conclu un accord d’induction de warrants pour accélérer l’exercice des warrants existants pour jusqu’à 7 360 460 actions à un prix réduit de 0,54 $ par action, générant environ 4,0 millions de dollars de produits bruts, avec une fenêtre d’offre permettant de lever jusqu’à 0,4 million de dollars supplémentaires. En contrepartie, les investisseurs recevront de nouveaux warrants non enregistrés pour acheter jusqu’à 14 720 920 actions à 0,54 $, exerçables après l’approbation des actionnaires et expirant cinq ans après la Date d’approbation. Le closing est prévu aux alentours du 17 octobre 2025. Le produit net est destiné au fonds de roulement et aux besoins généraux de l’entreprise. A.G.P./Alliance Global Partners a agi en tant que conseiller financier exclusif.
Theriva Biologics (NYSE American: TOVX) hat eine warrant-induzierte Vereinbarung getroffen, um das Ausüben bestehender Warrants für bis zu 7.360.460 Aktien zu einem reduzierten Preis von 0,54 USD pro Aktie zu beschleunigen, was Bruttoeinnahmen von ca. 4,0 Mio. USD erzeugt, mit einem Angebotsfenster, das bis zu zusätzlichen 0,4 Mio. USD aufnehmen kann. Im Gegenzug erhalten Investoren neue nicht registrierte Warrants zum Kauf von bis zu 14.720.920 Aktien zu 0,54 USD, ausübbar nach der Zustimmung der Aktionäre und fünf Jahre nach dem Genehmigungsdatum verfallend. Der Abschluss wird voraussichtlich am oder um den 17. Oktober 2025 erfolgen. Das Nettoeinkommen ist vorgesehen für Betriebskapital und allgemeine Unternehmenszwecke. A.G.P./Alliance Global Partners fungierte als exklusiver Finanzberater.
Theriva Biologics (NYSE American: TOVX) أبرمت اتفاقية حوافز بموجبها لتسريع تمكين ممارسة warrants الموجودة حتى 7,360,460 سهماً بسعر مخفض قدره $0.54 للسهم الواحد، مما يولد عوائد إجمالية تقارب $4.0 مليون دولار، مع نافذة عرض لجمع ما يصل إلى $0.4 مليون إضافية. في المقابل، سيحصل المستثمرون على warrants جديدة غير مسجلة لشراء حتى 14,720,920 سهماً بسعر $0.54، قابلة للإجراء بعد موافقة المساهمين وتنتهي صلاحيتها بعد خمس سنوات من تاريخ الموافقة. من المتوقع الإغلاق في نحو 17 أكتوبر 2025. تعتبر العوائد الصافية مخصصة لرأس المال العامل ولأغراض الشركات العامة. عملت A.G.P./Alliance Global Partners كمستشار مالي حصري.
Theriva Biologics (NYSE American: TOVX) 已签署一项权证诱导协议，以加速行使现有权证，最多可达7,360,460股，价格为每股$0.54美元，产生约$4.0百万美元的总募集额，并设有一个发行窗口可再额外筹集至$0.4百万美金。作为回报，投资者将获得新的未注册权证，购买最多14,720,920股，价格为$0.54，在股东批准后可行权，并在批准日后五年到期。预计于大约2025年10月17日完成。净募集资金用于营运资金和一般企业用途。A.G.P./Alliance Global Partners 担任独家财务顾问。
- Immediate gross proceeds of $4.0 million
- Potential additional exercise window up to $0.4 million
- Exclusive financial advisor: A.G.P./Alliance Global Partners
- Potential issuance of 14,720,920 new warrants
- Existing warrants exercised at $0.54 — dilutive to shareholders
- New warrants exercisable only after stockholder approval, creating timing risk
Insights
Warrant inducement raises
The company secured immediate cash by inducing holders to exercise up to 7,360,460 existing warrants at a reduced price of
This transaction supplies near-term working capital while postponing substantive dilution until the New Warrants become exercisable and the company files the resale registration statement. Key dependencies include shareholder approval timing and successful SEC registration; those items determine when the New Warrants convert to stock and the ultimate cash inflow from their exercise. Watch for the closing around
Structure trades immediate liquidity for contingent future dilution through a sizable pool of new warrants.
The deal converts existing warrants into immediate cash at a reduced exercise price and grants replacement New Warrants that total twice the number of shares underlying the exercised warrants. The company intends to use net proceeds for working capital and general corporate purposes, and the New Warrants and underlying shares remain unregistered until the company files a registration statement.
Material items to monitor are the registration filing and the stockholder approval that triggers New Warrant exercisability; both affect when holders can convert and whether the company obtains additional cash from future exercises. The near-term effect is improved liquidity; the medium-term effect depends on shareholder approval and whether warrant holders exercise, which will affect share count and capital raised over a multi-year window ending five years after the Approval Date.
ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced its entry into a warrant inducement agreement with existing institutional investors of the Company for the immediate exercise of warrants to purchase up to 7,360,460 of common stock (the “Existing Warrants”) at a reduced exercise price of
In consideration for the immediate exercise in full of the Existing Warrants, the investors will receive, in a private placement, new unregistered warrants to purchase up to an aggregate of 14,720,920 of common stock shares (the “New Warrants”). The New Warrants will have an exercise price of
A.G.P./Alliance Global Partners acted as the exclusive financial advisor in connection with the transaction.
The New Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act and, along with the common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the “SEC”) or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of common stock issuable upon exercise of the New Warrants.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Theriva™ Biologics, Inc.
Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary Theriva Biologics, S.L. , has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead clinical-stage candidates are: (1) VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients); and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva’s website at www.therivabio.com.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and include statements regarding the intended use of proceeds from the warrant inducement transaction, the anticipated closing of the warrant inducement transaction, the potential of VCN-12 to significantly improve antitumor effects; the feasibility of VCN-01 intracranial administration for the potential treatment of brain tumors; and the further development of VCN-01 as a therapeutic option for patients with brain tumors .These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the anticipated closing of the warrant inducement transaction on or about October 17, 2025; the Company’s intended use of the net proceeds from the warrant inducement transaction; the Company’s product candidates, including VCN-01 and VCN-12, demonstrating safety and effectiveness in clinical indications, as well as results that are consistent with prior results; the ability to confirm VCN-12 preclinical data in the clinical setting; the Company’s ability to reach clinical milestones when anticipated including enrolling the expected number of patients in each trial; the ability to complete clinical trials on time and achieve the desired results and benefits; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to promote or commercialize their product candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of the Company’s products, developments by competitors that render such products obsolete or non-competitive, the Company’s ability to maintain license agreements, the continued maintenance and growth of the Company’s patent estate, the ability to continue to remain well financed, and other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Theriva undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Investor Relations:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
FAQ
What is the total gross proceeds from Theriva Biologics' warrant inducement (TOVX)?
How many shares will be issued if existing warrants are exercised in Theriva's deal (TOVX)?
How many new warrants will investors receive in the Theriva (TOVX) private placement?
When will the new warrants from Theriva (TOVX) become exercisable and when do they expire?
What will Theriva (TOVX) use the net proceeds from the warrant inducement for?
When is the closing date for Theriva Biologics' warrant inducement transaction (TOVX)?
